Background-Pulmonary arterial hypertension is a disorder of vascular remodeling causing increased resistance to pulmonary blood flow. The expression of proteins in lungs from pulmonary arterial hypertension patients was investigated in an unbiased approach to further understand the pathobiology of this disease. Methods and Results-Label-free liquid chromatography tandem mass spectrometry was used to compare protein profiles in surgical samples of lungs from 8 patients with pulmonary arterial hypertension and 8 control subjects. More than 300 proteins were detected. On the basis of robust criteria, the levels of 25 proteins varied between the 2 groups. The majority of upregulated proteins were associated with cell growth, proliferation, and cell metabolism. Novel findings included an increased expression of chloride intracellular channel 4, receptor for advanced glycation end products, and periostin. Increased expression of chloride intracellular channel 4, a multifunctional protein involved in angiogenesis, and several signaling pathways implicated in pulmonary arterial hypertension-transforming growth factor-␤, vascular endothelial growth factor, and bone morphogenetic protein-was confirmed by Western blotting and localized predominantly to endothelial cells in occlusive and plexiform vascular lesions. Conclusions-Label-free proteomics identified differences in the expression of several proteins in the pulmonary arterial hypertension lung, many of which are relevant to the disease process. Increased expression of chloride intracellular channel 4 may be pertinent to the disorganized angiogenesis of plexiform lesions.
P ulmonary arterial hypertension (PAH) is a syndrome characterized by increased pulmonary vascular resistance and remodeling, leading to right ventricular failure and death. It includes idiopathic PAH (IPAH) and heritable PAH (HPAH), as well as PAH associated with a variety of conditions (including connective tissue diseases and congenital heart disease). Even with targeted vasodilator therapy, the annual mortality rate (15%) remains high. 1 Histological analysis of lungs from affected patients demonstrates marked vascular remodeling involving all elements of the blood vessel wall-endothelial cells, vascular smooth muscle, and adventitial fibroblasts-causing narrowing of the vessel lumen and vascular stiffening, resulting in increased pulmonary vascular resistance to blood flow. The biology of the morphological changes in the pulmonary vessels is poorly understood. Imbalances in expression and activity of vasoactive factors, dysregulated growth factors, and the infiltration of immune and inflammatory cells have all been implicated. 1
Clinical Perspective on p 2067
The investigation of candidate factors or pathways may overlook the complex interactions that drive and compensate for the vascular changes. A system-based unbiased screening method such as proteomics is better suited to capturing the broader view. Previous proteomic studies have focused mostly on the lung proteome of rodent models of PAH 2,3 or on investigating the role of specific antigen targets in human plasma. 4 This study reports for the first time the changes in protein expression in the lungs of PAH patients detected using label-free liquid chromatography tandem mass spectrometry (LC-MS/MS).
Methods

Lung Tissues
Tissue samples were obtained with the informed consent of patients and the approval of the Brompton Harefield & NHLI and Hammersmith Hospitals Research Ethics committees. Surgical samples of lung tissue were acquired from PAH patients at lung transplantation (nϭ20; 16 female patients; Table 1 ). Control tissues (nϭ16; Table 1 ) comprised uninvolved regions of lobectomy specimens from patients undergoing surgery for bronchial carcinoma (nϭ14; 6 female patients) and unused donor lungs (2 male patients with subarachnoid hemorrhage). Tissues were transported on ice, and samples for protein extraction were snap-frozen between 0.5 and 4.0 hours before being stored at Ϫ80°C until further analysis; transport times for both control and PAH samples were similar. Tissue samples (excluding large vessels and airways) suitable for proteomic and Western blot analyses were collected from peripheral regions of the lung. Additional tissue samples were fixed in 10% formal-saline and embedded in wax, and sections were processed for immunohistochemistry as previously described. 5
Proteomics Analysis
Lung tissue homogenates from each sample were separated by SDS-PAGE. After in-gel digestion of the separated proteins, tryptic peptides were analyzed by LC-MS/MS. Data analysis was performed by applying various criteria to ensure certainty in the assignment of protein identifications and to select those that were differentially expressed. This is summarized as a flow diagram (Figure 1 ), and a detailed description of the methods is provided in the online-only Data Supplement.
Western Blot Analyses and Immunohistochemistry
Western blot analyses were performed with antibodies against human chloride intracellular channel 1 (CLIC1), chloride intracellular channel 4 (CLIC4), periostin, haptoglobin, and vinculin. Immunohistochemistry studies for CLIC4 and periostin were performed on cryosections of human lungs. Details of these methods are provided in the online-only Data Supplement.
Results
The clinical characteristics of the PAH patients are summarized in Table 1 . The mean age of the PAH patients and 
Proteomic Differential Expression Analysis
Comparative proteomic analysis was performed on lung samples from 8 patients with PAH (7 IPAH and 1 HPAH) and 8 control subjects ( Table 1 ). None of the PAH patients used in this analysis had received targeted vasodilator therapy ( Table 1 ). Initial separation of proteins was by SDS-PAGE.
Stained gels showed that all samples contained relatively high levels of albumin (region R9) and haptoglobin (region R12; Figure 2 ). The gel was divided into a series of regions by molecular weight, and proteomic analysis was performed on each of them. Only proteins identified on the basis of at least 3 unique peptides were considered. With the stringent filtration criteria applied ( Figure 1 ), a total of 362 proteins were identified from regions R1 through R20 ( Table I in Table II in the online-only Data Supplement). Overall, there was little evidence of ex vivo proteolytic digestion, indicating that the samples were not degraded during collection or processing and were suitable for quantitative analyses.
The distribution of all of the detected proteins in the PAH and control groups is illustrated in a volcano plot ( Figure 3 ). Altogether, 25 proteins were differentially expressed. Of these, the levels of 18 proteins were higher and 7 were lower in the PAH group (Table 2) . When standardized against vinculin, 6 proteins that had lower expression in the PAH group showed no significant differential expression between groups ( Table 2 ). Similar results were obtained when the data were standardized against other structural proteins such as F-actin and vimentin (data not shown).
We selected some proteins for validation by Western blotting. These included periostin and haptoglobin, which had the highest and lowest differences in relative abundance, respectively; proteins with Ͼ1 member of its family (CLIC1 and CLIC4) displaying increased abundance; and a structural protein (vinculin) that was not significantly different between the 2 groups.
Western Blot Analyses
Consistent with the LC-MS/MS data, Western blot analysis of 14 PAH (13 IPAH and 1 HPAH) and 14 control lung samples ( Table 1) showed that CLIC1, CLIC4, and periostin levels were increased, haptoglobin levels were reduced, and vinculin levels unchanged in PAH compared with control tissues (Figure 4 ). There was a high correlation (rϾ0.9, linear regression analysis) between the abundances of these proteins as determined by LC-MS/MS and Western blot analysis ( Figure 5 ).
Immunohistochemistry
CLIC4 immunoreactivity was localized to the epithelium of bronchi and bronchioles, alveolar type II cells, and macrophages in lobectomy and donor lung tissues ( Figure 6A and 6B). Weaker immunostaining was seen in the alveolar walls and pulmonary vasculature, with staining of the endothelium predominating ( Figure 6C ). In IPAH lung tissues, CLIC4 was prominent in the endothelium of remodeled pulmonary arteries, exhibiting a distribution similar to that of the endothelial marker CD31, whereas cells in the medial and neointimal layers displayed only relatively weak immunoreactivity (Figure 6D and 6F). Immunostaining was also prominent in the Table 2 for a complete list). endothelial channels in plexiform lesions ( Figure 7A through 7C). Control sections developed with nonimmune IgG were devoid of any immunostaining.
Periostin showed a distinct distribution pattern to CLIC4, with no immunostaining apparent in the endothelium of pulmonary arteries or airway epithelium. In contrast, periostin was localized in the submucosa of bronchi and bronchioles and distributed in the alveolar walls ( Figure 8A ). Periostin immunostaining was also prominent in the airways and remodeled pulmonary arteries of IPAH patients ( Figure  8B through 8H). In the wall of remodeled vessels, periostin immunostaining was typically found in the neointimal rather than medial layer and generally displayed a distribution pattern differential to that of ␣-smooth muscle actin ( Figure  8C through 8H).
Discussion
This study was conducted in lung tissues from treatmentnaïve patients. Of Ͼ300 proteins detected, 25 were found that varied in abundance between PAH and control lung tissue on the basis of stringent criteria. Of these, 18 were upregulated and 7 were downregulated. The majority of the more abundant proteins in PAH could be associated with roles in cell growth, proliferation, intracellular trafficking, and signaling. Further confidence in the data comes from the detection of proteins that have been reported by others to change, confirmation by Western blotting and immunohistochemistry, and biological plausibility.
Detection of Known Protein Changes
Several of the proteins found to be upregulated in the lungs of PAH patients, including annexin A3, CLIC1, and four-and- a-half LIM domains protein 1 (FHL1), have also been reported to be increased in rodent models of pulmonary hypertension, induced by either long-term exposure to hypoxia or monocrotaline injection. 2,3 Kwapiszewska and coworkers 3 focused on one of these proteins and demonstrated increased FHL1 mRNA and/or protein expression in tissue extracts and pulmonary vascular lesions in the lungs of IPAH patients and pulmonary artery vascular smooth muscle cells in culture. The presence of FHL1 in isolated pulmonary artery vascular smooth muscle cells is of particular interest because it was shown to be regulated by hypoxia-inducible factors, and increased FHL1 expression was accompanied by enhanced migration and proliferation. 3 The present study provides the first independent data substantiating increased FHL1 expression in lung tissues from patients with PAH.
Novel Findings
We found increased levels of CLIC4 in lung tissues from PAH patients and validated this by Western blotting. The predominant localization of CLIC4 in occlusive and plexiform vascular lesions was in endothelial cells, with lower levels of immunostaining in neointimal and medial cells. CLIC4 is deemed to be a multifunctional protein that contributes to a number of signaling pathways, including those involved with transforming growth factor-␤, vascular endothelial growth factor, and bone morphogenetic proteins, 6,7 all of which have been implicated in the pathogenesis of PAH. 1 CLIC4 has recently been defined as a novel factor in RhoA signaling, cytoplasmic CLIC4 being rapidly translocated to the plasma membrane in response to RhoA activation. 8 In fact, CLIC4 modulates a variety of cell processes that are pertinent to pulmonary vascular remodeling and the disorganized angiogenesis found in plexiform lesions. These include the migration of pulmonary artery vascular smooth muscle cells 7 and integral steps in angiogenesis such as endothelial vacuole formation and tubulogenesis. 9, 10 In addition to CLIC4, the expression of other potential angiogenic mediators was enhanced in lung tissues from PAH patients, including annexin A3. 11 As far as we are aware, this study provides the first demonstration of increased expression of receptor for advanced glycosylation end products (RAGE) (also known as advanced glycosylation end product-specific receptor) in lung tissues from PAH patients. Activation of RAGE mediates endothelial dysfunction and inflammatory processes in chronic vascular disease and is considered a marker of inflammatory disease and injury in the lung. 12, 13 RAGE is expressed at low levels in normal tissues and vasculature and is upregulated wherever its ligands accumulate. 14 RAGE ligands include S100/calgranulins, and a member of this calcium-binding protein family (S100A4/Mts1) has been localized to vascular lesions in PAH and associated with the development of plexiform-like lesions in S100A4/Mts1overexpressing mice. 15 Subsequent investigations also demonstrated a role for S100A4/Mts1-RAGE signaling in the migration and proliferation of human pulmonary artery vascular smooth muscle cells in culture. 7, 16 In addition, these studies provided evidence of crosstalk with serotonin 16 and bone morphogenetic protein signaling, the latter being associated with the regulation of CLIC4 levels and activation of RhoA and Rac1. 7 Increased abundance of the transcriptional activator protein Pur-alpha is of interest because it belongs to a protein family that binds to DNA and functions as transcriptional repressors. 17 Indeed, Pur-alpha protein is implicated in the transforming growth factor-␤1-dependent expression of ␣-smooth muscle actin, opposing the effects of Smad proteins and thereby the activation of human pulmonary cells such as myofibroblasts. 18 The regulatory role of Pur-alpha and associated transcription factors may be significant in modulating myofibroblast differentiation and occlusive vascular remodeling in PAH.
We found increased periostin levels in lung tissues from patients with PAH and validated the periostin observation by Western blotting. Periostin is a secreted protein (so-called matricellular protein) that acts as a cytokine or humoral factor rather than having a direct structural role. 19 Periostin is considered to be involved in the response to vascular injury and regulation of smooth muscle cell proliferation, and increased periostin mRNA has been described in the lungs of chronically hypoxic rats. 20 Li and coworkers 20,21 also observed that periostin immunoreactivity was present in both airways and pulmonary vessels in the hypoxic rat lung and that expression in isolated pulmonary artery vascular smooth muscle cells was modulated by growth factors, atrial natriuretic peptide, and cGMP. In the present study, the distribution of periostin in human lung tissues by immunostaining was associated predominantly with the airways and alveolar walls, although it was also localized to the neointimal layer in remodeled pulmonary arteries in IPAH patients.
Among other induced proteins that were relatively abundant in the PAH lung, we also identified microfibrillarassociated glycoprotein 4 and tropomyosin ␣-4 chain. Microfibrillar-associated glycoprotein 4 is an extracellular matrix protein previously localized to the interalveolar sep- tum and wall of pulmonary arteries in human lung, 22 and increased tropomyosin ␣-4 chain expression has been associated with phenotypic changes in vascular smooth muscle cells in atherosclerotic lesions. 23 Expression of agrin, a heparan sulfate proteoglycan, was also increased in the PAH lung. Agrin has been best characterized in skeletal muscle, where it has a key function in the formation and maintenance of the neuromuscular junction, but little is known about its role in tissues such as the lung. 24 A further group of proteins found to be upregulated in the lungs of PAH patients are associated with endosomal transport, the Golgi apparatus, and caveolae assembly. These include the EpS15 homology domain (EHD) proteins such as EHD1 25 and serum deprivation-response protein. 26 Proteins like these may be affected by changes in caveolin-1 expression in PAH and modulate membrane-associated intracellular trafficking, thereby influencing endosomal and receptor signaling pathways for growth factors and cytokines in pulmo- nary artery endothelial and smooth muscle cells. 27 Indeed, 2 recent studies have emphasized the potential contribution of defective intracellular trafficking and Golgi dysfunction in the pathogenesis of pulmonary vascular remodeling and pulmonary hypertension. 28, 29 Serum deprivation-response protein (or cavin-2) is 1 of 4 caveolae regulatory proteins (or cavins). It acts as a substrate for protein kinase C, is expressed together with cavin-1 in the lung, and modulates caveolae formation. 30 In addition to the upregulated proteins found in PAH lung tissues, we identified a distinct group of proteins that were depleted compared with lobectomy control tissues. Serum proteins predominated in this group and included several acutephase proteins. This was unexpected, given that the hemostatic and fibrinolytic functions of the endothelium are affected, thrombotic lesions and platelet dysfunction are common features in PAH, and inflammatory processes are thought to have a key role in pulmonary vascular remodeling in PAH. 31, 32 It is noteworthy that these are largely circulating proteins; the origin of the proteins in the samples assayed for this study is unclear. However, when standardized against a structural protein (vinculin), except for haptoglobin, the difference was not evident, suggesting that these proteins may have originated from blood and not from the lung proteome.
Haptoglobin is considered to have significant antioxidant and antiinflammatory properties because of its ability to bind hemoglobin, and haptoglobin depletion could add to vascular dysfunction in the hypertensive lung. 33 This might also affect the expression of other proteins because in silico analysis has been used to identify a group of genes that are coexpressed with haptoglobin and hemopexin and modulated in their absence. 34 Studies of circulating haptoglobin in various forms of pulmonary hypertension have described reduced 35, 36 and increased haptoglobin levels. 37 Gene microarray experiments have been conducted to examine differences in pulmonary RNA expression in lung tissues from patients with severe end-stage pulmonary hypertension. 38, 39 Although numerous differentially expressed genes were identified that distinguished patients with IPAH, HPAH, and pulmonary hypertension associated with fibrotic lung and normal controls, it is apparent that there is little correspondence with the changes we observed in protein expression in lung tissues from PAH patients. This is perhaps not surprising given the regulatory mechanisms that control gene expression at the posttranscriptional and transcriptional levels. 40 Indeed, regulatory RNAs-microRNAs-that control gene expression posttranscriptionally modulate diverse cell functions and have been implicated in the pathogenesis of PAH. 41
Study Limitations
One limitation of this study is that lung tissue obtained at the time of transplantation represents nearly end-stage disease. This proteome analysis will not necessarily detect early changes, and findings may be dominated by repair and other compensatory mechanisms.
A second is that the proteomic approach was based on statistical analysis of the relative levels of peptides (and hence proteins) expressed in lung tissues from several patients with PAH and control subjects. Variation resulting from interindividual differences was incorporated into the analysis, but the size and complexity of the information produced and analysis of the proteomic data sets are challenging. We therefore focused on the most robust differences in protein expression and considered only those that exceeded predetermined limits of detection (Ն3 peptides), probability (PϽ0.05), and Ϯ1.5-fold difference. It is evident, however, that this will result in some affected proteins being omitted from the analysis, including proteins already implicated in the disease process. For example, previous investigations have demonstrated differences in phosphodiesterase type-5 and caveolin-1 protein levels in lung tissues from patients with IPAH, 5, 42 but neither was included in the differentially expressed protein list in the present study. In fact, we detected both phosphodiesterase type-5 and caveolin-1 in the lung samples, but in most cases, they were represented by just a single identified peptide (Figures III and IV in the online-only Data Supplement) and therefore failed to meet the inclusion criteria. To detect and quantify such proteins, it may be necessary to adapt the protocol to accommodate increased amounts of sample, undertake repeat analysis, and/or use instrumentation with increased sensitivity. Refinement of the methods of data analysis may also reveal further useful information. Nevertheless, even within the current limitations, the proteomic approach has revealed significant differences in the expression of numerous proteins the PAH lungs, many of which are biologically plausible and may be relevant to the disease process.
